At the news
? BULLISHIMPACT 6/10 8-K filed Jun 22, 2026 at 07:09 ET
TScan Therapeutics reported positive initial data from Cohort C of the ALLOHA Phase 1 study for TSC-101, showing 11 of 14 patients achieved complete donor chimerism within ~3 weeks of first infusion, with a 93% response rate and a ~90% manufacturing success rate using the commercial-ready process. The company remains on track to enroll the first patient in the pivotal Phase 3 ALLOHA-2 study this month, de-risking the program and supporting advancement toward a registrational trial.
- 11 of 14 patients achieved complete donor chimerism within ~3 weeks of first TSC-101 infusion
- 93% of patients (13/14) responded with decreasing recipient chimerism
- ~90% manufacturing success rate (17/19) with commercial-ready process
- Safety profile consistent with Cohort A; no new safety signals
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access